BOSTON, June 15, 2015 /PRNewswire/ -- PAREXEL
International Corporation (NASDAQ: PRXL), a leading global
biopharmaceutical services provider, today announced that
Alberto Grignolo, PhD, Corporate
Vice President, PAREXEL Consulting, was awarded the DIA Global
Connector Award. DIA presented the award at the 2015 DIA
Global Inspire Awards event during the 51st Annual Drug
Information Association (DIA) Meeting in Washington, D.C. The honor recognizes
Dr. Grignolo's meritorious service through a leadership role that
has advanced the mission of DIA to foster innovation and to improve
health and well-being worldwide.
"We are proud that our colleague, Alberto Grignolo, received the 2015 DIA Global
Connector Award. Alberto has demonstrated his superior
understanding of drug development and the unique way he can
connect, navigate, and bring people together for a common cause,"
said Josef von Rickenbach, Chairman
and CEO, PAREXEL International.
Dr. Grignolo is a global expert and frequent speaker on the
topics of drug development, drug regulatory affairs, and the
Japanese regulatory environment. He currently serves on the faculty
of DIA's Regulatory Affairs training courses and as the Deputy
Editor of DIA's member magazine, Global Forum.
At PAREXEL, Dr. Grignolo developed the Company's Worldwide
Regulatory Affairs and Drug Development Consulting Practice.
Recently, he established PAREXEL's Japan Consulting Services during
a two-year assignment in Tokyo. He
is the Executive Sponsor of a number of global development programs
and advises clients in the areas of drug development strategy,
regulatory negotiation, and best regulatory and clinical
practices.
At the DIA 2015 Annual Meeting, Dr. Grignolo is chairing two
sessions:
- Japan Regulatory Environment: Overview of the Organization,
Processes, Systems, and Changes Affecting Pharmaceutical
Development
- Emerging Practices in Product Commercialization Planning: How
Cross Collaboration Is Redefining Product Development Planning
"As a member and volunteer with DIA for more than 30 years, Dr.
Grignolo has demonstrated exceptional dedication to the
organization and to advancing the mission through his many
roles. I can think of no one more deserving of the 2015 DIA
Global Connector Award," said Barbara Lopez
Kunz, Global Chief Executive, DIA.
About DIA's Inspire Awards
DIA's annual Inspire Awards are awarded to members who have a
record of making a difference in the eco-system of health care
product development and lifecycle management.
About PAREXEL International
PAREXEL International Corporation is a leading global
biopharmaceutical services organization, providing a broad range of
expertise-based contract research, consulting, medical
communications, and technology solutions and services to the
worldwide pharmaceutical, biotechnology and medical device
industries. Committed to providing solutions that expedite
time-to-market and peak-market penetration, PAREXEL has developed
significant expertise across the development and commercialization
continuum, from drug development and regulatory consulting to
clinical pharmacology, clinical trials management, medical
education and reimbursement. PAREXEL Informatics, Inc. provides
advanced technology solutions, including medical imaging, to
facilitate the clinical development process. Headquartered near
Boston, Massachusetts, PAREXEL
operates in 80 locations in 51 countries around the world, and had
approximately 17,440 employees in the third quarter. For more
information about PAREXEL International visit www.PAREXEL.com.
PAREXEL and PAREXEL Informatics are trademarks or registered
trademarks of PAREXEL International Corporation or its
affiliates. All other trademarks are the property of their
respective owners.
This release contains "forward-looking" statements regarding
future results and events, including, without limitation,
statements regarding expected financial results, future growth and
customer demand. For this purpose, any statements
contained herein that are not statements of historical fact may be
deemed forward-looking statements. Without limiting the
foregoing, the words "believes," "anticipates," "plans," "expects,"
"intends," "appears," "estimates," "projects," "will," "would,"
"could," "should," "targets," and similar expressions are
also intended to identify forward-looking statements. The
forward-looking statements in this release involve a number of
risks and uncertainties. The Company's actual future results
may differ materially from the results discussed in the
forward-looking statements contained in this release.
Important factors that might cause such a difference include, but
are not limited to, risks associated with: actual operating
performance; actual expense savings and other operating
improvements resulting from restructurings; the loss, modification,
or delay of contracts which would, among other things, adversely
impact the Company's recognition of revenue included in backlog;
the Company's dependence on certain industries and clients; the
Company's ability to win new business, manage growth and costs, and
attract and retain employees; the Company's ability to complete
additional acquisitions, and to integrate newly acquired businesses
including the acquisitions of ClinIntel Limited and Quantum
Solutions India, or enter into new lines of business; the impact on
the Company's business of government regulation of the drug,
medical device and biotechnology industry; consolidation within the
pharmaceutical industry and competition within the
biopharmaceutical services industry; the potential for significant
liability to clients and third parties; the potential adverse
impact of health care reform; and the effects of foreign currency
exchange rate fluctuations and other international economic,
political, and other risks. Such factors and others are
discussed more fully in the section entitled "Risk Factors" of the
Company's Quarterly Report on Form 10-Q for the quarter ended
March 31, 2015 as filed with the
Securities and Exchange Commission on May 1,
2015, which "Risk Factors" discussion is incorporated by
reference in this press release. The Company specifically
disclaims any obligation to update these forward-looking statements
in the future. These forward-looking statements should not be
relied upon as representing the Company's estimates or views as of
any date subsequent to the date of this press release.
Contacts:
Diana Martin, PAREXEL
International
Tel: +1 781-434-5516
Email: Diana.Martin@PAREXEL.com
Cristi Barnett, PAREXEL
International
Tel.: +1 781-434-4019
Email: Cristi.Barnett@PAREXEL.com
Jenny Gardynski, PAN
Communications
Tel: +1 617-502-4300
Email: PAREXEL@pancomm.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/parexel-executive-honored-with-2015-dia-global-connector-award-300098530.html
SOURCE PAREXEL International Corporation